<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140151</url>
  </required_header>
  <id_info>
    <org_study_id>ML29258</org_study_id>
    <nct_id>NCT02140151</nct_id>
  </id_info>
  <brief_title>Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Eyes With Nonexudative AMD Trial: A Multicenter, Prospectively Randomized, Masked and Controlled, Interventional Investigator Sponsored Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Desert Retina Consultants, MC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California Desert Retina Consultants, MC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether quarterly injections of Ranibizumab may prevent eyes with
      dry age-related macular degeneration from progressing to wet age-related macular degeneration
      (AMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospectively randomized, masked and controlled, interventional
      investigator sponsored phase I/II study of subjects with high-risk nonexudative age-related
      macular degeneration (AMD) treated with intravitreal ranibizumab quarterly for prophylaxis of
      conversion to exudative age-related macular degeneration.

      The objective of this study is to investigate the safety and efficacy of prophylactic
      anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab to prevent the
      development of exudative AMD in eyes with high-risk nonexudative AMD. In addition, baseline
      characteristics of high-risk eyes (fundus features, optical coherence tomography (OCT)
      parameters and genetic profile) will be evaluated to determine their predictive value in
      conversion to exudative AMD. The effect of ranibizumab on the atrophic component of AMD will
      also be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of exudative AMD</measure>
    <time_frame>2 years</time_frame>
    <description>Development of choroidal neovascularization (conversion) defined by the presence of leakage on fluorescein angiography (FA) and fluid within or below the retina or below the retinal pigment epithelium seen on spectral-domain optical coherence tomography (SD-OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vision change</measure>
    <time_frame>2 years</time_frame>
    <description>Change in best-corrected visual acuity (BCVA) from baseline at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision loss</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of eyes losing &lt; 5, 10, and 15 letters on EDTRS chart at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections</measure>
    <time_frame>2 years</time_frame>
    <description>Number of injections required in eyes that convert from dry to wet AMD during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline predictive factors</measure>
    <time_frame>2 years</time_frame>
    <description>Baseline demographic, genetic and ocular characteristics predictive of development of wet AMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of geographic atrophy (GA)</measure>
    <time_frame>2 years</time_frame>
    <description>Development of geographic atrophy (GA) as detected by fundus photography (FP) and/or fundus autofluorescence (AF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and severity of ocular adverse events, as identified by eye examination and imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and severity of other adverse events, as identified by physical examination or subject reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Sham Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quarterly Ranibizumab 0.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quarterly intravitreal injection of 0.5mg ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <arm_group_label>Quarterly Ranibizumab 0.5mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult over 50 years old

          -  Able to sign informed consent and comply with the study protocol for the duration of
             two years

          -  Nonexudative age-related macular degeneration (AMD) in one eye (study eye)

          -  History of exudative AMD in one eye only (fellow eye) diagnosed within 5 years of
             study enrollment

        Exclusion Criteria:

          -  Participation in another simultaneous medical investigation or clinical trial

          -  Patient is pregnant, lactating, or premenopausal and not using adequate contraception

          -  Known serious allergies to ranibizumab, fluorescein dye, drugs for pupillary dilation,
             topical anesthetic, sterilizing solution (e.g. Betadine solution)

          -  Presence of ocular conditions with increased risk of choroidal neovascularization
             (CNVM) or pigment epithelial detachment (PED), including presumed ocular
             histoplasmosis syndrome (POHS), traumatic choroidal rupture, angioid streaks,
             pathologic myopia (spherical equivalent of ≥ -8 diopters or axial length of ≥ 25 mm),
             multifocal choroiditis, macular choroidal nevus, polypoidal choroidal vasculopathy
             (PCV), idiopathic central serous chorioretinopathy (ICSC), etc.

          -  History of vitrectomy in the study eye

          -  History of cataract surgery within 3 months of enrollment

          -  History of yttrium aluminum garnet (YAG) capsulotomy within 1 month of enrollment

          -  History of intraocular or periocular corticosteroid therapy within the past 90 days

          -  History of therapeutic radiation in the region of the study eye.

          -  Presence of media opacity that would preclude adequate examination and/or imaging

          -  Concurrent macular conditions that would affect the study parameters (epiretinal
             membrane, macular hole, macular edema) or require treatment within the duration of the
             study

          -  Any progressive ocular condition (uncontrolled glaucoma, diabetic retinopathy,
             uveitis) that may affect the visual acuity for the duration of the study

          -  Active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye
             at enrollment

          -  Presence of any advanced systemic condition that may hinder the patients participation
             and completion of the study

          -  Concurrent use of systemic anti-VEGF therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maziar Lalezary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California Desert Retina Consultants</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maziar Lalezary, MD</last_name>
    <phone>760-340-2394</phone>
    <email>mlalezary@desertretina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Depaz</last_name>
      <phone>650-988-7480</phone>
      <email>sdepaz@ncrva.com</email>
    </contact>
    <investigator>
      <last_name>Alok Bansal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Wieland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul Khurana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Palmer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Walther</last_name>
      <phone>760-340-2394</phone>
      <phone_ext>229</phone_ext>
      <email>kwalther@desertretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Maziar Lalezary, MD</last_name>
      <phone>760-340-2394</phone>
      <email>mlalezary@desertretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maziar Lalezary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clement K Chan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven G Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elman Retina</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Belz</last_name>
      <phone>410-553-9095</phone>
      <email>belz@elmanretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Joann Starr</last_name>
      <phone>410-553-9095</phone>
      <email>starr@elmanretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Elman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Livermont</last_name>
      <phone>605-719-3307</phone>
      <email>klivermont@bhrei.com</email>
    </contact>
    <investigator>
      <last_name>Prema Abraham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arunan Sivalingam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amd</keyword>
  <keyword>non-exudative macular degeneration</keyword>
  <keyword>exudative macular degeneration</keyword>
  <keyword>age-related macular degeneration</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

